Navigation Links
VISULAS YAG III Laser Capsulotomy Systems

ProductsVISULAS YAG III Laser Capsulotomy Systems
Company Carl Zeiss Meditec, Inc.
Item VISULAS YAG III Laser Capsulotomy Systems
Features 
  • Safe: The Super-Gaussian beam profile ensures that optical breakdown is achieved with very low pulse energies. The result: fewer side effects for the patient and less risk.
  • Precise: The 4-point aiming beam system facilitates the ability to focus with extreme precision and to detect any astigmatic distortion before firing the laser.
  • Ergonomic: The design guarantees unobstructed visual contact with the patient and free access to the eye. The control console contains a large illuminated display for menu-guided operation.
Description The VISULAS YAG III is the new disruption laser from Carl Zeiss Meditec designed in particular for applications in posterior capsulotomy (post-cataract therapy) and iridotomy. However, the YAG laser is also used for trabeculotomy, anterior capsulotomy and for IOL polishing. It's another milestone in the development of state-of-the-art, practice-oriented ophthalmic laser systems for photodisruption.
Info Carl Zeiss Meditec, Inc.Call Carl Zeiss Meditec, Inc. to buy products (US and Canada only; other locations use number below) USACanada1-866-407-6044

Customer Service: 877-486-7473
Web site: http://www.meditec.zeiss.com/

Related medicine products :

1. VISULAS 532s
2. VISULAS 690s Photodynamic Therapy Laser System
3. VISULAS YAG III Combi Complete Laser Therapy System
4. Full Handle Laseredge Stab Blade Knife, 15 blade
5. Full Handle Laseredge Stab Blade Knife, 15 blade, 3 mm
6. Full Handle Laseredge Stab Blade Knife, 22.5 blade
7. Full Handle Laseredge Stab Blade Knife, 45 blade
8. Full Handle Laseredge Stab Blade Knife, 30 blade
9. Full Handle Laseredge Crescent Blade Knife, angled bevel up
10. Full Handle Laseredge Crescent Blade Knife, straight
11. Full Handle Laseredge Crescent Blade Knife, angled double bevel
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl
Utilizing breakthrough electro-optical and rotary prism technology, the new RM-8000B SUPRA is capable of obtaining perfectly accurate refraction measurements through pupils as narrow as 2.0mm. This m
Sterile free isotonic balanced salt solution
Sterile perfluorocarbon for intraocular Application.
Medicine Products:
(Date:8/20/2008)...n, adult females, but not in men, study finds , ...lcoholism is associated with delayed childbearing ...,s and men,s lifetime history of alcohol dependenc..., The researchers analyzed data from two groups... female and 1,880 male twins) and between 1964-19...
(Date:8/20/2008)...e/ -- WXYZ- TV/Channel 7 and The,Detroit Departmen...ands of,Detroit metro area children a "boost" at t...This year the program will be held Sunday, August ...Wright Museum of African,American History. Since i...s provided free immunizations to over 50,000 young...
(Date:8/20/2008)...swire-FirstCall/ -- Tianyin,Pharmaceutical, Co., I...rer,and supplier of modernized traditional Chinese...nnounced that the Company,s stock symbol had been,...electronic eligibility,system error., The error i...cts the,stock symbol to trade under the symbol OTC...
(Date:8/20/2008)...urteen physicians who have been,part of Commonweal...enhance,the care and service they provide to their...are top-notch primary care physicians, and we are ...on," said Nick Turkal, M.D., Aurora,s,president an...king with,them to support their care of patients i...
Breaking Medicine News(10 mins):Health News:Women's Alcohol Use Tied to Delayed Childbearing 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction 2Health News:Commonwealth Medical Group Physicians to Join Aurora Health Care 2
...ho have implanted devices in their hearts face ris...ake arteries patent or open to allow an easy passa...s by surgeons.Stents may be medicated or non medic...o suffer from internal blood clotting. The risk is...
...keenly studied the effect of discontinuing HIV dru...red. The results can be positively// devastating, ...e has published the results of this current resear...ntinued, the patients face a greater chance of dev...
...s that are used in treatment of cancer, are likely...y a research, published by the Journal of Biology.... in brain damage. The effects may be long lasting....enon termed 'chemobrain'.Chemobrain refers to the ...
...e to consume junk food which is over laden with sa...f traditional home made food. This has resulted in...er concentration of salt as their salt receptors a...s like childhood hypertension and early developmen...
Other Medicine News:Health News:Using Heart Stents Tends to Form More Clots 2Health News:Interrupted Treatment Dangerous to HIV Management 2
(Date:8/18/2008)...ndings offer hope for increased life expectancy fo.../PRNewswire-USNewswire/ -- In the world of Down,sy...rogress has been,tracked for the past 16 years, at...ife expectancy of a person with Down syndrome, cur...,Mr. C, was born. Further, ,Mr. C, does,not exhibi...
(Date:8/18/2008)...Leader with Strong Clinical Research Relationships...nizations to Lead Commercialization, SANTA CLARA,...io, Inc.,(OTC Bulletin Board: NWCI) a cardiac dia... Vincent W. Renz has joined NewCardio as its presi...alization effort, to include,business development,...
(Date:8/17/2008)...Australia, Aug. 17 /Xinhua-...ed that the first pivotal Phase 3,clinical trial o...has,completed enrolment., The first efficacy data... the first half of 2009. The trial commenced its d...ruitment target of 250 subjects in June,2008 and c...
(Date:8/14/2008)... A Complimentary Continuing Education Activity, ...ovirus (CMV) is a,significant cause of morbidity a...ell transplantation. The clinical manifestations o...estinal disease to life-threatening,pneumonia, mye...rder to prevent CMV infection and reduce CMV drug ...
Breaking Medicine Technology:Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 2Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 3Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 1Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 2Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 3Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 4Study Suggests Risperidone Long Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2962 5HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora Ontario Wal Mart Store 23 5778 10831 1HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora Ontario Wal Mart Store 23 5778 10831 2HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora Ontario Wal Mart Store 23 5778 10831 3HearAtLast Expands Chain to 18 Locations Opening New Clinic in Aurora Ontario Wal Mart Store 23 5778 10831 4IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 1IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 2IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 3IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 4IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 5IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 6IDM Pharma Announces Phase 3 Mifamurtide 28L MTP PE 29 Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 1304 7Biopure Launches Updated Website 2955 1Biopure Launches Updated Website 2955 2
...gium, March 28, 2007,/PRNewswire-FirstCall/ -- Bio...lts of a sample collection study aimed at,identify...n the,assessment for risk of sepsis progression. S...rapeutic options. Clinical investigator,Emanuel P...,research at the department of emergency medicine ...
...e World,s First Commercial Vaccine,for Travellers,...mpletes Phase I Clinical Trials , ,Trial confirms ...ENSE, Denmark, March 28, 2007 -ACE BioSciences A/S...nounce the successful,completion of Phase I clinic...,s first commercial vaccine for Travellers,Diarrh...
Other Medicine Technology:Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 2Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 3Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 4Biosite Reports on Presentation of Preliminary Data From Sepsis,Program 5Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 2Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 3Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 4